Daily Stock Analysis, CLDX, Celldex Therapeutics Inc, priceseries

Celldex Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
4.03
Close
3.77
High
4.08
Low
3.67
Previous Close
3.97
Daily Price Gain
-0.20
YTD High
11.62
YTD High Date
Feb 4, 2019
YTD Low
3.00
YTD Low Date
Jan 2, 2019
YTD Price Change
0.01
YTD Gain
0.29%
52 Week High
12.58
52 Week High Date
May 7, 2018
52 Week Low
2.75
52 Week Low Date
Dec 26, 2018
52 Week Price Change
-7.41
52 Week Gain
-66.27%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 22. 2017
39.90
Oct 17. 2017
45.00
17 Trading Days
12.77%
Link
LONG
Mar 5. 2018
36.15
Mar 13. 2018
38.80
6 Trading Days
7.34%
Link
LONG
Aug 21. 2018
6.59
Sep 4. 2018
7.22
9 Trading Days
9.55%
Link
LONG
Jan 4. 2019
3.57
Feb 8. 2019
6.91
24 Trading Days
93.49%
Link
Company Information
Stock Symbol
CLDX
Exchange
NasdaqGS
Company URL
http://www.celldex.com
Company Phone
908-200-7500
CEO
Anthony S. Marucci
Headquarters
New Jersey
Business Address
53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ 08827
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000744218
About

Celldex Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes therapeutic antibodies, antibody drug conjugates, vaccines, and immune system modulators. The company's drug candidates include Glembatumumab vedotin, Varlilumab, CDX-1401, CDX-301, and Rintega. Celldex Therapeutics was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Description

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers. In addition, the company focuses on the discovery and development of antibody-based drugs targeting receptor tyrosine kinases, such as CDX-0158, a humanized monoclonal antibody currently in a Phase 1 dose escalation study in refractory gastrointestinal stromal tumors and other KIT positive tumors; and CDX-3379, a human monoclonal antibody, which has completed a Phase 1b study in patients with solid tumors. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. The company is headquartered in Hampton, New Jersey.